Dingkai Medical Announces $60M Series B Financing to Target China's Vascular Intervention Market

October 8: Yioou Health learned from insiders that DK Medtech announced today the completion of its RMB 60 million Series B financing round.Financing, this round of financing was led by Qiming Venture Partners, with Heyu No. 1 as a co-investor.It is reported that this is another round of financing for DK Medtech following its RMB 20 million funding round last year. This round of financing will be used to advanceCardiovascularInterventionConsumablesclinical trials and registration, expand the R&D pipeline for other vascular interventional products, and gradually build a commercial team. Additionally, Weng Yulin, Founder and CEO of DK Medtech, stated that while the company is rooted in cardiovascular interventions, it is also positioning itself in other emerging high-potential markets, such as peripheral vascular interventions.

Cardiovascular disease is the leading cause of death globally, with up to 15 million people dying from it each year worldwide, accounting for 20–30% of all global deaths. In China, with socioeconomic development and particularly the accelerating aging of the population, the prevalence of cardiovascular risk factors has become increasingly pronounced, the number of cases continues to rise, and rapid growth is expected over the next decade. Currently, the main treatment modalities include surgical replacement, bypass grafting, and stent implantation.

DK Medtech, established in 2015, is a company specializing in the research and development and manufacturing of vascular interventional medical treatment products. Currently, multiple products have entered the registration application and clinical trial stages, targeting the future 10 years in ChinaInterventional Marketthe trend of continuously launching domestically produced medical devices as substitutes for imports.

Regarding the Launch of Domestically Produced Alternative Medical Devices,Weng Yulin stated that, from the perspective of healthcare insurance cost containment, domestic substitution is a prevailing trend. Theoretically, DK Medtech is poised to outperform foreign medical enterprises. While foreign companies pioneered the initial innovations (from 0 to 1), DK Medtech has built upon overseas samples and data, gaining in-depth insights into the needs of the Chinese market, physicians, and patients, thereby implementing improvements to enhance performance and user experience.

Company Team, DK Medtech currently has 14 employees. Its founder and CEO, Weng Yulin, was formerly a key technical expert at Biosensors (Biosensors International Group, Singapore) and has launched multiple star products in Europe, Japan, China, and other regions. RegardingWeng Yulin has his own perspective on maintaining a lean team. He believes that, from a micro perspective, offering employees higher compensation while assigning them greater responsibilities enables rapid learning and growth, thereby enhancing their sense of professional fulfillment. From a macro perspective, this approach minimizes internal friction within the company, directs resources precisely to critical areas, and genuinely drives corporate development.

In the venture capital community, everyone is crying out about a "capital winter," with investment trends becoming increasingly cautious.Weng Yulin stated that DK Medtech’s current round of financing has proceeded smoothly, with the team’s efforts gaining recognition from the capital market. The company’s products under development are progressing well. The participation of Qiming Venture Partners and Heyu No. 1 will significantly promote the company’s growth and provide financial support for subsequent R&D products. DK Medtech will expedite the market launch of its products to ensure that patients in China benefit at an earlier date.

It is understood that, unlike other companies that sequentially develop and launch individual products, DK MedtechThey tend to build a comprehensive product portfolio from the outset. After obtaining regulatory approval for smaller products exempt from clinical trials, they refine their commercialization strategies and scale up manufacturing capabilities. This prepares them to achieve smoother market coverage when their core products launch around 2020.

Regarding the investment in DK Medtech, Hu Xubo, Managing Partner at Qiming Venture Partners, stated,DK Medtech’s founding team possesses years of industry experience in cardiovascular devices, with proven expertise in the successful development of international interventional products and a deep understanding of the domestic clinical market. This is why Qiming Venture Partners is bullish on DK Medtech.

The policy orientation of “Healthy China 2030” has directly driven the continuous expansion of a trillion-yuan market. Meanwhile, the “Several Opinions on Promoting the Development of the Health Service Industry” have also charted the course for the broader health industry. Innovators are constantly emerging in various niche sectors, including scientific living, health management, and health consumption. Amidst these new opportunities, how can one seize the moment to achieve overtaking on a bend? And how should investments in the big health sector identify promising projects?

November 30, 2018, China World Summit Wing, Beijing,2018 EO Innovators Annual Conference [Great Health Innovators Forum]Special Open Free Registration:https://www.iyiou.com/post/ad/id/709

Copyright Notice

All content sourced from YiOu.com is copyrighted by Beijing YiOu Network Alliance Technology Co., Ltd. The views expressed in the articles are those of the authors and do not imply endorsement or support by YiOu.